IP Library › Granted Patent US 10,202,606
Granted Patent B2
US 10,202,606 · App. 15/022,856 · Granted Feb 12, 2019

Complex containing oligonucleotide having immunopotentiating activity and use thereof

Inventors: Ken Ishii (Ibaraki, JP); Kouji Kobiyama (Ibaraki, JP); Taiki Aoshi (Ibaraki, JP); Fumihiko Takeshita (Tokyo, JP); Yuji Kasuya (Tokyo, JP); Takako Niwa (Tokyo, JP); Makoto Koizumi (Tokyo, JP)
Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION; DAIICHI SANKYO COMPANY, LIMITED
C12N15/117A61K31/713A61K31/7125A61K39/12A61K39/145A61K39/155A61K39/39C07H21/04C08B37/0024C12N7/00A61K2039/5252A61K2039/55561A61K2039/55583C12N2310/17C12N2310/315C12N2310/351C12N2310/3519C12N2320/31C12N2760/16134C12N2760/18534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,202,606
App. No.
15/022,856
Granted
Feb 12, 2019
Kind
B2
Abstract

The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3′-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and β-1,3-glucan.

Claims (34)

1. A complex comprising:

(i) an oligodeoxynucleotide comprising humanized K type CpG oligodeoxynucleotide consisting of the nucleotide sequence shown by SEQ ID NO: 1 and poly deoxyadenylate of 20-60 nucleotide length,

wherein the poly deoxyadenylate is bound at the 3′-end of the humanized K type CpG oligodeoxynucleotide, and

wherein all of the phosphodiester bonds are substituted by phosphorothioate bonds; and

(ii) lentinan.

2. The complex according to claim 1 , having a triple helix structure.

3. The complex according to claim 1 , having an activity to activate B cells to produce IL-6, and an activity to activate dendritic cells to produce IFN-α.

4. A pharmaceutical composition comprising the complex according to claim 1 .

5. A method for the treatment or prophylaxis of an infectious disease in a warm-blooded animal, comprising administering a pharmacologically effective amount of the complex according to claim 1 and an antigen to the warm-blooded animal, wherein the antigen is therapeutic or prophylactic for the infectious disease.

6. The method according to claim 5 , wherein the infectious disease is a virus infection or intracellular parasitic protozoan or bacterial infection.

7. The method according to claim 6 , wherein the virus infection is RS virus or influenza virus infection.

8. The method according to claim 5 , wherein the warm-blooded animal is human.

9. A method of inducing a protective immune reaction in a warm-blooded animal, comprising administering a pharmacologically effective amount of the complex according to claim 1 and an antigen to the warm-blooded animal, wherein the antigen is therapeutic or prophylactic for an infectious disease.

10. A pharmaceutical composition comprising

(a) the complex according to claim 1 , and

(b) an antigen.

11. The composition according to claim 10 , wherein the antigen is derived from a pathogen.

12. The composition according to claim 11 , wherein the pathogen is a virus.

13. The composition according to claim 12 , wherein the virus is an RS virus or influenza virus.

14. A method for inducing an immune reaction to an antigen in a warm-blooded animal, comprising administering an effective amount of the complex according to claim 1 and the antigen.

15. The method according to claim 14 , wherein the antigen is derived from a pathogen.

16. The method according to claim 15 , wherein the pathogen is a virus.

17. The method according to claim 16 , wherein the virus is an RS virus or influenza virus.

18. The method according to claim 14 , wherein the warm-blooded animal is human.

19. A method for the treatment or prophylaxis of an infection with a pathogen in a warm-blooded animal, comprising administering a pharmacologically effective amount of the complex according to claim 1 and an antigen derived from the pathogen to the warm-blooded animal.

20. The method according to claim 19 , wherein the pathogen is a virus.

21. The method according to claim 20 , wherein the virus is an RS virus or influenza virus.

22. The method according to claim 19 , wherein the warm-blooded animal is human.

23. A method for inducing production of type I and/or type H interferon in a warm-blooded animal, comprising administering an effective amount of the complex according to claim 1 to the warm-blooded animal.

24. A method for enhancing immune response to an antigen in a warm-blooded animal, comprising administering an effective amount of the complex according to claim 1 together with the antigen to the warm-blooded animal.

25. The method according to claim 24 , wherein the antigen is derived from a pathogen.

26. The method according to claim 25 , wherein the pathogen is a virus.

27. The method according to claim 26 , wherein the virus is an RS virus or influenza virus.

28. The method according to claim 24 , wherein the warm-blooded animal is human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2016
From: ISHII, KEN; KOBIYAMA, KOUJI; AOSHI, TAIKI; TAKESHITA, FUMIHIKO; KASUYA, YUJI; NIWA, TAKAKO; KOIZUMI, MAKOTO
To: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION; DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 038019/0759 →
Priority Claims (1)
JP 2013-196206 · Sep 20, 2013 · national
Continuity (1)
Related Publication 20160208260A1 · Jul 21, 2016
Cited By (1)
US 12,227,745